Replies to post #164505 on Biotech Values

[mcbio]

Insulin FoB’s are a mediocre business proposition, IMO. MNTA is not pursuing this market.

Biocon is pursuing generics of Lantus, Humalog, and Novolog, which collectively had 2012 net sales of $11.5B. How are potential generics of those three drugs a mediocre business proposition?